Navigation Links
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
Date:9/10/2007

will be available through Sept. 14, 2007.

About TRU-015 and SMIP(TM) Therapeutics

Trubion and Wyeth Pharmaceuticals are developing small modular immunopharmaceutical (SMIP(TM)) therapeutics directed to CD20, an antigen present on B cells. In addition to the ongoing development of TRU-015 for RA, investigational new drug applications have been filed for TRU-015 for systemic lupus erythematosus and non-Hodgkin's lymphoma. Trubion's SMIP drug candidates represent a novel class of immunotherapeutics that the company believes possess enhanced drug properties over monoclonal and recombinant antibodies. SMIP product candidates are novel single-chain polypeptide proteins designed using Trubion's custom drug assembly technology. Trubion's current product candidates bind to specific antigen targets on a cell's surface that have been clinically validated as important in disease management either by existing products or by potential products in clinical trials.

About Rheumatoid Arthritis

RA is a chronic disease, mainly characterized by inflammation of the lining, or synovium, of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. According to Datamonitor, RA is estimated to affect approximately 4.3 million people in the United States, Japan and Europe. In 2006, total reported worldwide sales of protein therapeutics used for the treatment of RA were greater than $9.5 billion.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatmen
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... N.C. , May 24, 2013  Regulatory ... the forefront of many organizations, priority list. ... medical device sectors understand a strong Medical ... challenges in clinical development, market education , ... to create a vital bridge between an organization ...
(Date:5/24/2013)... FRANKLIN LAKES, N.J. , May 24, 2013  BD ... leading global medical technology company, announced today that it will ... Care Conference on Thursday, May 30, 2013, at 10:40 a.m. ... can be accessed from the BD corporate website at ... June 6, 2013.    About BD ...
(Date:5/24/2013)... , May 24, 2013 /PRNewswire-iReach/ -- Phoenix Houses ... non-profit substance abuse services organization, is hosting its tenth ... Hills Hotel on June 6, 2013.  More than 300 ... funds for the adolescent residential treatment centers, family therapy, ... honor individuals whose accomplishments have positive influences on the ...
Breaking Medicine Technology:Building Medical Affairs Capabilities to Ensure Organizational Success across Key Operational Areas 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3
... 31, 2011  PLC Systems Inc. (OTCBB: PLCSF), a ... device-based technologies, today announced that its new product, ... Disease and Contrast Nephropathy, a 90 minute ... November 7-11, 2011 in San Francisco, California.  ...
... 31, 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China ... ), a leading fully integrated pharmaceutical company in the People,s ... a conference call at 9:00 a.m. Eastern Time (ET) on ... 2011 financial results. A full version of the Company,s quarterly ...
Cached Medicine Technology:PLC Systems' RenalGuard® to be Featured in Chronic Kidney Disease and Contrast Nephropathy Session at TCT 2011 2PLC Systems' RenalGuard® to be Featured in Chronic Kidney Disease and Contrast Nephropathy Session at TCT 2011 3PLC Systems' RenalGuard® to be Featured in Chronic Kidney Disease and Contrast Nephropathy Session at TCT 2011 4China Sky One Medical Announces Conference Call to Discuss Third Quarter 2011 Results 2
(Date:5/24/2013)... May 24, 2013 Dwell Media ... Brandon Huff as Executive Vice President of Digital for ... units, which represented a large portion of Yahoo's global ... as Dwell develops a fully-integrated commerce unit to launch ... experience monetizing digital content for leading firms in Silicon ...
(Date:5/24/2013)... (HealthDay News) -- People with high levels of cadmium ... of liver disease than those with lower levels, a ... in urine is evidence of long-term exposure to the ... tobacco smoke, the Johns Hopkins researchers explained. They ... directly causes liver disease but instead suggest an association ...
(Date:5/24/2013)... According to the National Institutes of Health, Stevens Johnson ... that affects the skin and mucous membranes. SJS occurs ... of 30 (i). In the early stages SJS presents ... SJS advances, it affects the mucous membranes such as the ... of the eye causes conjunctivitis (pink eye). Inflammation of ...
(Date:5/24/2013)... 2013 American Career College (ACC), a ... participated in festivities surrounding the 2013 Toyota Grand Prix ... the perfect backdrop to introduce the community to the ... Street, housed in an architectural gem known to Long ... an active exhibitor throughout the weekend festivities. The college’s ...
(Date:5/24/2013)... one in five parents think they have little control ... illicit drug use, a new U.S. government survey finds. ... Abuse and Mental Health Services Administration (SAMHSA), since new ... most influential forces helping to shape their child,s views ... show that parents can make an enormous difference in ...
Breaking Medicine News(10 mins):Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:American Career College Revs Up Community Support During Toyota Grand Prix of Long Beach 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2
... Americans with muscular dystrophy die 10 to 12 years younger ... Sept. 14 issue of Neurology , the medical journal ... gap, which was calculated on the basis of 20 years ... annals of research into racial disparities in health care, say ...
... Colorado at Boulder study sheds light on the brain mechanisms ... helpful in improving treatments for the millions of people who ... study, CU-Boulder psychology Professor Yuko Munakata and her research colleagues ... nerve cell suppresses activity in another, is a critical aspect ...
... National Hispanic Science Network on Drug Abuse awarded the ... Investigator to Alice Cepeda, sociology professor and associate director ... Graduate College of Social Work, University of Houston. ... annual conference in New Orleans. , The National ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... levels of thimerosal, a mercury-laden preservative that used to be ... autism than infants exposed to only a little thimerosal, new ... who worry that vaccination raises their children,s risk for autism, ...
... 13 (HealthDay News) -- Women can be vulnerable to ... part of a condition called preeclampsia. And now ... which women are most prone to preeclampsia in late ... relies on so-called "metabolic profiling" to track telltale metabolites ...
... mental aging reveals a good news-bad news situation. The bad ... to varying degrees. The good news is the drops are ... study published by the American Psychological Association. "There ... called crystallized intelligence decline at older ages," said study author ...
Cached Medicine News:Health News:Blacks with muscular dystrophy die 10-12 years younger than whites: New study 2Health News:CU-Boulder study sheds light on how our brains get tripped up when we're anxious 2Health News:CU-Boulder study sheds light on how our brains get tripped up when we're anxious 3Health News:University of Houston researcher receives National Award of Excellence in Research 2Health News:More Evidence That Vaccines Don't Cause Autism 2Health News:More Evidence That Vaccines Don't Cause Autism 3Health News:Test Might Spot Women at High Risk for Pregnancy Complication 2Health News:Test Might Spot Women at High Risk for Pregnancy Complication 3Health News:New study reconciles conflicting data on mental aging 2Health News:New study reconciles conflicting data on mental aging 3
... 10% Ash: 1.6% ... Gel pH (1.5%): 5.0 7.0 Gel Point ... 95C A (430 nm, 1.5%): 0.150 ... 25,000 Ohms EEO (-m r ): ...
... incubators is available, ensuring the customers to ... specific requirements. miniTHERM incubators have a capacity ... space saving. Their size corresponds approximately to ... to stack up to three units on ...
... range of miniTHERM incubators is available, ensuring ... solution for their specific requirements. miniTHERM incubators ... compact and extremely space saving. Their size ... It is possible to stack up to ...
DH Autoflow Single Chamber Stackable Air-Jacketed CO2 Incubator...
Medicine Products: